Clinical Trial

Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 4, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.
Trial Details
NCT Number NCT06956196
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Atopic Dermatitis
Enrollment 240 participants
Start Date 2025-05
Primary Completion 2026-05 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-05-04